Final Program

WEDNESDAY • MAY 18 339
• learn new findings about the identification and validation of new asthma drug
targets;
• screen drug candidates that improve lung function;
• gain knowledge on GPCR signaling in the lung.
There is still an urgent need to develop new and improved therapy for asthma.
G-protein coupled receptors (GPCRs) are the targets of more than 50% of all known
pharmaceuticals. Current mainstay asthma therapies including beta-agonists,
anticholinergics, and leukotriene inhibitors, all directly target GPCRs. Recent studies
have identified several GPCRs and many of them unexpectedly as new potential
targets for asthma therapy. In this session, we will bring a high-caliber list of experts
to discuss the latest developments in this exciting area that promises to change the
face of asthma medicine in the coming decades.
Chairing: Q. Lu, PhD, Boston, MA
R. Penn, PhD, Philadelphia, PA
9:00 Targeting Calcium Sensing Receptor (CaSR) in Allergic
Asthma
D. Riccardi, PhD, Cardiff, United Kingdom
9:20 Function and Targeting of Proton-Sensing GPCR OGR1 in ASM
R. Penn, PhD, Philadelphia, PA
9:40 Bitter Taste Receptors as Targets for Novel Bronchodilators
D.A. Deshpande, PhD, Philadelphia, PA
10:00 Screening GPCR Targets with Force
R. Krishnan, PhD, Boston, MA
10:20 Structural Insights into ß2-Adrenergic Receptor Signaling
R. Sunahara, PhD, La Jolla, CA
10:40 Cholecystokinin (CCK) and Its Receptor CCKAR as Novel
Therapeutic Targets for Asthma
Q. Lu, PhD, Boston, MA
This session and the International Conference are supported by an educational grant from
AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
D8
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
ATS MYTHBUSTERS: ABERRANT TISSUE
REGENERATION IS A PRIMARY DRIVER OF COPD
PATHOGENESIS
Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology
and Inflammation; Clinical Problems; Critical Care; Environmental,
Occupational and Population Health; Microbiology, Tuberculosis and
Pulmonary Infections; Pulmonary Circulation; Pulmonary Rehabilitation;
Respiratory Structure and Function; Thoracic Oncology
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2016/2018 (West Building, Level 2)
Target Audience
Lung health care providers, scientists and investigators interested or involved in
basic, translational and clinical research related to lung biology and clinical
aspects of COPD and related human lung diseases. Research and care
providers engaged in pulmonary and critical care medicine.
Objectives
At the conclusion of this session, the participant will be able to:
• understand how aberrant airway and alveolar regeneration contributes to the
pathogenesis of airway remodeling, emphysema and inflammation in COPD;
• learn how aberrant tissue repair mechanisms interact with other components
of COPD pathogenesis (oxidative stress, inflammation, altered innate
immunity and host-microbe interactions);
• understand how to translate the novel knowledge about the role of aberrant
tissue regeneration in COPD pathogenesis into clinically relevant
“personalized” (precision medicine) approaches to better prevent, diagnose
and treat COPD.
This session continues the “ATS Mythbusters” series focused on emerging areas
of translational lung biology and medicine. The central theme of the current ATS
Mythbuster session is recently evolved concept of abnormal airway and alveolar
structural maintenance and regeneration as the driving force of COPD
pathogenesis and progression. Recently developed data supporting this novel
concept (“myth”) will be presented by the investigators who contributed to these
discoveries and then discussed by internationally recognized leading scientists
(“busters”) in the COPD field.
Chairing: R. Shaykhiev, MD, PhD, New York, NY
I. Petrache, MD, Denver, CO
J.C. Hogg, MD, PhD, Vancouver, Canada
9:00 Introduction to the Myth: Emerging Non-inflammatory Origins
of COPD
I. Petrache, MD, Denver, CO
9:15 Altered Epithelial Barrier Function in COPD Airways
I.H. Heijink, PhD, Groningen, Netherlands
9:30 Pathologic Programming of Airway Basal Stem Cells in COPD
R. Shaykhiev, MD, PhD, New York, NY
9:45 Epithelial-Mesenchymal Interactions and Airway Fibrosis in
COPD
S. Nishimura, MD, San Francisco, CA
10:00 Wnt Signaling Shift in COPD and Aging
M. Konigshoff, MD, PhD, Munich, Germany
10:15 Telomere Dysfunction and Alveolar Stem Cell Failure in
Emphysema
M. Armanios, MD, Baltimore, MD
10:30 “Mythbusters” Discussion
L.M. Fabbri, MD, Modena, Italy
M. Saetta, MD, Padova, Italy
S.I. Rennard, MD, Melbourn, United Kingdom
P.J. Barnes, MD, DSc, London, United Kingdom
WEDNESDAY MORNING
ATS 2016 • San Francisco